# Ipamorelin Research: Mechanism, Key Studies, and the CJC-1295 Question

> Ipamorelin research read with a clinical eye — the selectivity mechanism, the human PK and failed Phase 2 trial, the CJC-1295 pairing, and how it compares to sermorelin and tesamorelin.

From the founding selectivity work to the failed human trial and the popular combinations — read in order, with the limits noted.

## The short version

Here is the research on ipamorelin in plain terms. It is a five-amino-acid peptide that flips one switch — the ghrelin receptor — to release a pulse of growth hormone, and it does that without raising the stress hormone cortisol [1]. That clean signal is the most-studied and best-supported thing about it.

The rest of the picture is smaller and more cautious. In people, one study mapped how fast it clears (a roughly two-hour half-life) [2], and one trial tested whether it helped bowel recovery after surgery — it did not [3]. Most other work is in rats, pigs, fish, and ferrets, and looks at bone growth, weight, and receptor biology [4] [5]. The popular "CJC-1295 + ipamorelin" combination has never been tested as a product in a human trial [15]. Below, each major finding gets its own section, with the species and dose kept visible so you can see exactly how strong — or thin — each piece of evidence is.

## What is ipamorelin peptide?

Ipamorelin peptide is a wholly synthetic pentapeptide — five amino acids, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular weight about 712 Da [1]. It was derived from the older peptide GHRP-1 by removing a central dipeptide, and two D-amino acids plus a non-natural amino acid (Aib) at position one make it resistant to being chewed up by enzymes. It is not a natural human peptide; it mimics the action of the natural hunger hormone ghrelin at the GHS-R1a receptor. Functionally, it is a growth hormone secretagogue — a compound that tells the pituitary to secrete growth hormone.

## How it works: selective GH release

Ipamorelin binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, which triggers a calcium-driven signaling cascade and a discrete pulse of growth hormone [1]. The headline finding from Raun and colleagues (1998) is selectivity: in rat pituitary cells, anaesthetised rats, and conscious pigs, GH release matched GHRP-6 (pig ED50 2.3 nmol/kg) while ACTH and cortisol stayed flat even above 200× the GH-active dose [1].

The mechanism generalizes across species in informative ways. In black seabream pituitary cells, ipamorelin released GH with nanomolar potency — but without changing GH gene transcription even at 48 hours, showing the receptor acts at the *secretory* level, releasing stored hormone rather than making more [8]. In live seabream, giving ipamorelin actually raised gastric ghrelin gene expression, revealing a feedback loop where the agonist boosts production of the receptor's own natural ligand [9].

## The human data: PK and a failed trial

Human evidence is limited and, where it tests outcomes, negative. A 1999 population PK/PD study (eight healthy men per dose level, five 15-minute IV infusions of 4.21–140.45 nmol/kg) found dose-proportional kinetics, a terminal half-life of about two hours, clearance of 0.078 L/h/kg, and a single GH pulse peaking near 40 minutes [2].

The one efficacy trial is the anchor. NCT00672074 gave 0.03 mg/kg IV twice daily for up to seven days to 114 bowel-resection patients and missed its primary endpoint — median time to first tolerated meal 25.3 h versus 32.6 h on placebo (p = 0.15) [3]. Treatment-emergent adverse events were actually slightly *lower* with ipamorelin (87.5%) than placebo (94.8%), so no drug-specific safety signal emerged in that short window — but neither did benefit [3]. No Phase 3 trial followed.

## Animal efficacy: bone, weight, and the freshest data

The supporting animal record is where the positive signals live. In adult female rats, subcutaneous ipamorelin at 18, 90, and 450 µg/day (split three times daily for 15 days) raised the longitudinal bone-growth rate dose-dependently from 42 µm/day (vehicle) to 44, 50, and 52 µm/day — with **no** change in total IGF-1 or bone-turnover markers, pointing to a partly local, GH-pulse-driven skeletal effect [4].

The most recent in-vivo study is a 2024 ferret cachexia model: intraperitoneal ipamorelin (1–3 mg/kg) cut cisplatin-driven body-weight loss by about 24% in the delayed phase, but had no anti-emetic effect on either acute or delayed vomiting [5]. The ipamorelin backbone has also served as a research scaffold — for boron-rich peptide conjugates that still activated GHS-R1a [10], and as one of several GHS pharmacophores tested for an 18F-PET ghrelin-receptor probe (the best probe was a different G-7039 analogue, so those affinity numbers are not ipamorelin's) [11].

## Ipamorelin cjc-1295

Ipamorelin cjc-1295 refers to pairing ipamorelin with CJC-1295, a GHRH analog. The logic is mechanistic: ipamorelin releases GH through the ghrelin receptor, while CJC-1295 works through the separate GHRH receptor, so the two pathways are complementary rather than redundant [1]. A 2026 orthopaedic narrative review reported that CJC-1295 + ipamorelin improved maximal muscle tetanic tension in a glucocorticoid-induced muscle-loss model in mice, while stressing the evidence is limited to animals [15]. Critically, the combination itself has never been tested in a human trial for any outcome — its support is the separate single-agent pharmacology, not a studied product.

## What is cjc 1295 ipamorelin?

What is cjc 1295 ipamorelin? It is the most popular peptide "stack" in this space: a GHRH analog (CJC-1295) combined with a ghrelin-receptor agonist (ipamorelin) to push growth hormone through two doors at once. CJC-1295 extends and amplifies the underlying GH baseline; ipamorelin adds discrete pulses without raising cortisol [1]. Community protocols give both subcutaneously, but no peer-reviewed human dosing or outcome data exist for the pair, and the available human and animal evidence on each agent is summarized — with citations — across this site [3] [15].

## Does cjc-1295 ipamorelin work?

For the combination specifically, there is no human outcome trial, so "works" rests on mechanism and animal data. The strongest combination finding is a mouse muscle-tension result in a glucocorticoid-induced muscle-loss model, reported in a 2026 review that explicitly limits it to animal evidence [15]. For ipamorelin alone, the lone human efficacy trial (postoperative ileus) failed [3], while animal studies show real effects on bone growth and weight [4] [5]. Honest reading: a plausible mechanism and supportive animal data, but no proof of a human benefit.

## Ipamorelin vs sermorelin

Ipamorelin vs sermorelin compares two different mechanisms. Sermorelin is a GHRH analog — it works on the GHRH receptor to amplify the body's own GH rhythm. Ipamorelin is a ghrelin-receptor agonist — it adds a separate pulse and, unlike GHRH analogs, can act independently of the GHRH pathway [1]. That difference is exactly why the two compound classes get combined rather than chosen against each other. On evidence, both are thin in humans; ipamorelin's one human efficacy trial failed [3], and neither has an approved performance or anti-aging indication.

## Ipamorelin vs tesamorelin

Ipamorelin vs tesamorelin is a contrast between an unapproved research peptide and an approved drug with a *narrow* approved use. Tesamorelin is a GHRH analog approved only for HIV-associated lipodystrophy; ipamorelin is a ghrelin-receptor agonist approved for nothing [3]. Mechanistically they hit different receptors — GHRH receptor versus ghrelin receptor — and the two classes are complementary. Comparing them as interchangeable "GH peptides" misreads both: tesamorelin has a specific labeled indication and human data behind it; ipamorelin's human record is one failed Phase 2 trial.

---

A tolerability-first console read of the ipamorelin literature — the reported side effects, the water-retention question, and the half-life logged plainly, the single failed human trial and the blank long-term-safety line kept in view; the 'md' names a reading lens, never a clinic, and nothing here is dosed, prescribed, or sold.